ANZCTR search results

This study looks at treatment with a targeted biological therapy (Epidermal Growth Factor Receptor [EGFR] Targeted, Paclitaxel Loaded EnGeneIC Delivery Vehicles [ErbituxEDVsPac]) in people with advanced epithelial cancer. Who is it for? You can join this study if you have: – advanced epithelial cancer which has spread to secondary or distant sites or cannot be removed by surgery – a tumour type known to express EGFR. Trial details All participants will receive ErbituxEDVsPac Dose at increasing doses. The study will monitor the safety and effectiveness of treatment, in particular the immune and inflammatory response (measured after each treatment) and the tumour response (measured after each six week cycle of treatment).

This study aims to better investigate the underlying problem behind the swallowing difficulties (dysphagia) experienced by many people diagnosed with inflammatory muscle disorders (Inclusion Body Myositis, Dermatomyositis and Polymyositis)

The aim of this study is to determine how adrenaline and clonidine affect the absorption of levobupivacaine in children having caudal anaesthesia for sub-umbilical surgery. Our study hypothesis is that the absorption of levobupivacaine will be affected when administered in conjunction with adrenaline and clonidine via the caudal route.

Increase the influence of fathers on infant feeding practices including initiation and duration of breastfeeding

There are two previous studies (Lynton, Kligler and Shiflett, 2007; Bastille and Gill-Body, 2004), which suggest yoga-based activity programs may be of benefit for stroke survivors but these studies have had quite small sample sizes and have not involved randomized control procedures, which prevent any firm conclusions. A sub study of the North East Melbourne Stroke Incidence Study (NEMESIS) has indicated that interventions which target physical impairment and mood have the potential to improve health-related quality of life in stroke survivors (Sturm et al, 2008). A yoga-based intervention may be able to provide benefits in terms of functional recovery and mood improvement due to its unique combination of exercise-like movements and meditation practices. Participation in yoga programs may be a cost effective, low side effect risk, option for addressing both physical and emotional disabilities in stroke survivors.

This study compares the effectiveness of pre-operative treatment with cisplatin, 5 fluorouracil and docetaxel with or without radiotherapy in treating people who have shown a poor early response to standard chemotherapy for adenocarcinoma of the oesophagus and/or gastroesophageal junction. Who is it for? You can join this study if you have localised adenocarcinoma of the oesophagus or gastroesophageal junction which is due to be treated by surgery. Trial details: After the first cycle of standard cisplatin/5-FU chemotherapy all patients will have a PET scan. Patients who have a poor response on the PET scan, will be randomly divided into two groups. One group will receive chemotherapy (cisplatin/5-FU with the addition of docetaxel) followed by surgery, and the other will receive chemotherapy (cisplatin/5-FU with the addition of docetaxel) and radiation followed by surgery. In both groups, the chemotherapy is given intravenously. In the group receiving radiation treatment, this will overlap with the chemotherapy treatment. The study aims to evaluate the response to the different therapy regimens, by comparing pathology samples, looking at the response on PET scans, toxicity, survival rates and quality of life.

This study aims to investigate the effectiveness of chiropractic treatment for the lower limb kinetic chian. We hypothesize the wider scope of treatment will provide better outcome in pain scores, overall effectiveness, range and motion and gait ability due to the inter-relationahip of the biomechanical change and addressing compensatory actions. We hope it will provide evidence to be included in guidelines for management of osteoarthritis and may provide alternative options to analgesics and surgery.

This study compares surgery using a laparoscope (keyhole surgery) compared with open surgery in treating colorectal (bowel) cancer. You can join this study if you have been diagnosed with primary cancer of the rectum or lower bowel (stage T 1-3 N 0-1 M 0-1) that requires surgery. Trial participants will be randomly divided into two groups. One group will receive surgery using a laparoscope (keyhole surgery) while the other will receive the standard open surgery. Patients will be assessed 6 weeks prior to surgery, with follow up checks at day 3 and day 14 post surgery, and then at 4–6 weeks, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months and annually at 3, 4 and 5 years. Surgical resection of the tumour is the most important treatment for rectal cancer. Laparoscopic-assisted techniques allow the tumour to be removed with smaller incisions, and less invasive surgery. This study aims to determine whether these new techniques offer a safe and viable alternative to standard surgery. The primary aim of this study will be to determine whether laparoscopic-assisted resection of rectal cancer is non-inferior (or equivalent) in safety and efficacy to the open technique of laparotomy and surgical resection. The secondary aim of the study will be to determine whether laparoscopic-assisted rectal resection is equivalent to open rectal resection in providing comparable recovery outcomes and in terms of disease recurrence and survival, and quality of life.

This study will evaluate the safety and efficacy of post-operative chemotherapy for 12 weeks versus 24 weeks in patients with locally advanced colon cancer. Who is it for? You may be eligible to join this study if you are 18 years or above and have stage III colon cancer which has been fully resected (i.e. removed by surgery). You should not have undergone any previous chemotherapy for your cancer. Trial details Participants in this trial will be randomly (by chance) allocated to one of two groups. Participants in one group will undergo chemotherapy for 12 weeks. Participants in the other group will undergo chemotherapy for 24 weeks. Chemotherapy will either be with the drugs oxaliplatin/5-FU or oxaliplatin/capecitabine depending on the preference of your treating doctor. Participants will be regularly assessed for a period of up to 7 years to determine disease free survival, overall survival, toxicity, cost effectiveness and quality of life.

The primary purpose of Part 1 of this study is to determine the safety and tolerability of 100 mg SCH 527123 when dosed for 14 days in healthy adult subjects. The information from this part will provide evidence for/against using 100 mg SCH 527123 in future trials that may involve patients (ie, COPD subjects) The primary purpose of Part 2 of this study is to determine the dose-response relationship between doses of SCH 527123 and compared with inactive treatment (placebo, sugar pill) and active treatment (prednisone). The information from this trial will be used to compare the oral mucosal neutrophil response between SCH 527123 with active (prednisone) and inactive (placebo) treatment.